3,4'-5-trihydroxystlbenes compounds with functions of reducing pulmonary artery high pressure and improving respiration function

Abstract

A 3',4',5-trihydroxystlbene compound for lowering the high tension of arteria pulmonalis and improving respiratory function is disclosed. It includes polydatin (or piceid) and resveratnol prepared by hydrolyzing polydatin.

Description

[0001] 1. Field [0002] The present invention belongs to the category of medicine (A61p11 / ), relates to a polydatin compound, in particular to a polydatin compound (polydatin, a compound with a stilbene triphenol structure) for reducing pulmonary hypertension and improving respiratory function ). 2. Background technology [0003] In recent years, due to environmental pollution and other reasons, the incidence and harmfulness of cor pulmonale have become increasingly serious, making the development of drugs that can effectively regulate pulmonary arterial pressure (hph) and prevent and treat cor pulmonale more important. At present, there are many related reports at home and abroad. Vasodilator drugs are the most researched drug therapy, but the clinical effect of existing therapeutic drugs is not satisfactory, this is because: (1) most of the existing drugs for lowering pulmonary arterial pressure (except inhaled NO) are for the treatment of hypertension The drug lacks speci...

AI Technical Summary

Problems solved by technology

Vasodilator drugs are the most researched drug therapy, but the clinical effect of existing therapeutic drugs is not satisfactory, this is because: (1) most of the existing drugs for lowering pulmonary arterial pressure (except NO inhalation) are used to treat hypertension Drugs, lacking specificity to pulmonary vessels, reduce pulmonary arterial pressure while also reducing systemic blood pressure, causing hypotensive reactions

(2) Most drugs that reduce pulmonary arterial pressure have a greater impact on the ventilation / blood flow ratio. While reducing blood pressure, the PaO will be lowered due to no improvement in ventilation. 2 Reduce and aggravate hypoxia, which is not good for the treatment of cor pulmonale

(3) Negative effect on the heart, reducing cardiac output and even aggravating heart failure

(4) The existing drugs for improving pulmonary hypertension have limited effects, and the pulmonary arterial pressure will rise again after drug withdrawal, which cannot be individualized or used outside the hospital

The technology of extracting polydatin from Polygonum cuspidatum is relatively mature. Although it has been reported at home and abroad, it has not been reported to develop it into a drug for systematic research, especially from the aspects of animal experiments and clinical research. Patent reports on the use of polydatin extracted from Chinese medicine to prevent and treat HPH, CCP, etc.